Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma Clinical Trial

Official title:

A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01217229
• Other study ID #: PLX108-03
• Status: Completed
• Phase: Phase 2
• Start date: March 3, 2011
• Est. completion date: April 26, 2012

Study information

• Verified date: June 2020
• Source: Daiichi Sankyo, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.The primary objective of this study is to evaluate the efficacy, as measured by overall response rate, of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin lymphoma (HL). Secondary objectives include safety, the duration of response, the disease control rate, progression free survival, and how the drug affects your body.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 26, 2012
• Est. primary completion date: April 26, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patients =18 years old

2. Pathologic confirmation of relapsed or refractory classical Hodgkin lymphoma, with archival or fresh tissue available for retrospective analysis.

3. Patients must have progressed after-or been ineligible for-autologous stem cell transplantation. Patients who received a prior allogeneic stem cell transplantation are eligible if they have no evidence of graft versus host disease (GVHD) and have been off immunosuppression for at least 3 months prior to Cycle 1 Day 1 (C1D1).

4. Documented disease that is radiographically measurable (=2 cm in the largest transverse dimension).

5. Patients must have discontinued any previous monoclonal antibody, radioimmunotherapy, or cytotoxic chemotherapy at least 28 days prior to C1D1 and must have recovered fully from the side effects of that treatment prior to beginning study treatment.

6. Women of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for 3 months after the last dose. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for =1 year. Men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug.

7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

8. Adequate hematologic, hepatic, and renal function (absolute neutrophil count =1.0 x 109/L, Hgb >9 g/dL, platelet count =50 x 109/L, Aspartate Transaminase (AST) / Alanine Transaminase (ALT) =2.5x Upper limit of normal (ULN), creatinine =1.5x ULN)

9. Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements

Exclusion Criteria:

1. Investigational drug use within 28 days of the first dose of PLX3397

2. History or clinical evidence of central nervous system, meningeal, or epidural disease including brain metastasis

3. Patients with another active cancer [excluding basal cell carcinoma or cervical intraepithelial neoplasia (cervical carcinoma in situ) or melanoma in situ]. Prior history of other cancer is allowed, as long as there was no active disease within the prior 5 years.

4. Patients with uncontrolled intercurrent illness, an active or uncontrolled infection, or a fever >38.5°C (not due to tumor fever) on C1D1

5. Refractory nausea and vomiting, malabsorption, biliary shunt, or significant bowel resection that would preclude adequate absorption

6. Patients with serious illnesses, medical conditions, or other medical history including abnormal laboratory results, which in the investigator's opinion would be likely to interfere with a patient's participation in the study, or with the interpretation of the results

7. Women of child-bearing potential who are pregnant or breast feeding

8. Corrected QT interval (QTc) =450 msec.

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma
• Lymphoma

Intervention

Drug:
• PLX3397
Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.

Locations

Country	Name	City	State
United States	Northwestern University, The Robert H Lurie Comprehensive Cancer Center	Chicago	Illinois
United States	MD Anderson Cancer Center	Houston	Texas
United States	UCLA Jonsson Comprehensive Cancer Center	Los Angeles	California
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	Nebraska Medical Center	Omaha	Nebraska
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Daiichi Sankyo, Inc.	Plexxikon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival According to the Cheson Criteria by Kaplan-Meier Analysis Following Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma (Modified Intent-to-Treat Population)	Progression-free survival was assessed by Kaplan Meier analysis and was defined as the number of days from the first day of treatment to the date of first documented disease progression or date of death (whichever occurred first).	Baseline to 1 year postdose
Primary	Summary of Overall Tumor Response and By Cycle Following Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma (Modified Intent-to-Treat Population)	Subjects were monitored for response and disease progression with contrast Computed tomography (CT) /18Fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans every two cycles. Each cycle is 28 days. Response to treatment as defined by Cheson criteria was reported via descriptive statistics. Target tumor response is Complete Response (CR) + Partial Response (PR) and target tumor disease control rate (CR + PR + Stable Disease (SD)) are reported. Per Cheson Criteria, CR is disappearance of all evidence of disease; Partial Response is regression of measurable disease and no new sites (=50% decrease in sum of product diameters of up to 6 largest dominant masses and splenic/liver nodules), and no increase in size of other nodes/liver/spleen; reduction in target lesions, no growth of non-target or new lesions; Progression is any new lesion or increase by =50% of previously involved sites from the nadir.	Baseline to Cycles 3, 5, 7, 10, and 13, up to 1 year postdose
Primary	Participants With Treatment-Emergent Adverse Events Occurring at a Frequency of =10% in Any Preferred Term (Safety Population)		Baseline to 1 year post-dose
Primary	Participants With at Least Grade 2 Severity Adverse Events by Preferred Term (Safety Population)	Grade 2 adverse events were defined as events that were moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL).	Baseline to 1 year postdose